Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep 7;8(11):2187-2190.
doi: 10.1016/j.ekir.2023.09.012. eCollection 2023 Nov.

Is Genotype the Major Outcome Parameter of Kidney Failure in Patients With Primary Hyperoxaluria Type 1?

P Sharmas Vali  1 , Bernd Hoppe  2
Affiliations
Editorial

Is Genotype the Major Outcome Parameter of Kidney Failure in Patients With Primary Hyperoxaluria Type 1?

P Sharmas Vali et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Urolithiasis or nephrocalcinosis and systemic oxalate depositions in patients with primary hyperoxaluria.
See this image and copyright information in PMC

Comment on

  • Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.
    Metry EL, Garrelfs SF, Deesker LJ, Acquaviva C, D'Ambrosio V, Bacchetta J, Beck BB, Cochat P, Collard L, Hogan J, Ferraro PM, Franssen CFM, Harambat J, Hulton SA, Lipkin GW, Mandrile G, Martin-Higueras C, Mohebbi N, Moochhala SH, Neuhaus TJ, Prikhodina L, Salido E, Topaloglu R, Oosterveld MJS, Groothoff JW, Peters-Sengers H. Metry EL, et al. Kidney Int Rep. 2023 Aug 4;8(10):2029-2042. doi: 10.1016/j.ekir.2023.07.025. eCollection 2023 Oct. Kidney Int Rep. 2023. PMID: 37849991 Free PMC article.

References

    1. Demoulin N., Aydin S., Gillion V., Morelle J., Jadoul M. Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis. 2022;79:717–727. doi: 10.1053/j.ajkd.2021.07.018. - DOI - PubMed
    1. Hoppe B., Martin-Higueras C. Improving treatment options for primary hyperoxaluria. Drugs. 2022;82:1077–1094. doi: 10.1007/s40265-022-01735-x. - DOI - PMC - PubMed
    1. Garrelfs S.F., Frishberg Y., Hulton S.A., et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384:1216–1226. doi: 10.1056/NEJMoa2021712. - DOI - PubMed
    1. Metry E.L. Determinants of kidney failure in primary hyperoxaluria type 1: findings of the European hyperoxaluria consortium. KI Rep. 2023;8:2029–2042. - PMC - PubMed
    1. Mandrile G., van Woerden C.S., Berchialla P., et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86:1197–1204. doi: 10.1038/ki.2014.222. - DOI - PubMed

LinkOut - more resources